{"id":185297,"date":"2025-10-21T06:17:22","date_gmt":"2025-10-21T05:17:22","guid":{"rendered":"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/"},"modified":"2025-10-21T06:17:22","modified_gmt":"2025-10-21T05:17:22","slug":"odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario","status":"publish","type":"post","link":"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/","title":{"rendered":"Odronextamab en pacientes con linfoma difuso de c\u00e9lulas B grandes reca\u00eddo\/refractario"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.infosalut.com\/images\/noticies\/institucions\/ins-epr159.jpg\" \/><\/p>\n<p>El Departamento de Hematolog\u00eda del\u00a0<a href=\"https:\/\/www.hospitalsonespases.es\/ca\" target=\"_blank\" rel=\"noopener\">Hospital Universitari Son Espases<\/a>\u00a0y el\u00a0<a href=\"https:\/\/www.idisba.es\/cat\/\" target=\"_blank\" rel=\"noopener\">Institut de Investigaci\u00f3n Sanit\u00e0ria de les Illes Balears<\/a> han participado en un estudio\u00a0de eficacia de monoterapia con odronextamab en pacientes con linfoma difuso de c\u00e9lulas B grandes reca\u00eddo\/refractario.<\/p>","protected":false},"excerpt":{"rendered":"<p>El Departamento de Hematolog\u00eda del\u00a0Hospital Universitari Son Espases\u00a0y el\u00a0Institut de Investigaci\u00f3n Sanit\u00e0ria de les Illes Balears han participado en un estudio\u00a0de eficacia de monoterapia con odronextamab en pacientes con linfoma difuso de c\u00e9lulas B grandes reca\u00eddo\/refractario.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[5],"tags":[],"class_list":["post-185297","post","type-post","status-publish","format-standard","hentry","category-noticias"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.9 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Odronextamab en pacientes con linfoma difuso de c\u00e9lulas B grandes reca\u00eddo\/refractario - bip4ex<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Odronextamab en pacientes con linfoma difuso de c\u00e9lulas B grandes reca\u00eddo\/refractario\" \/>\n<meta property=\"og:description\" content=\"El Departamento de Hematolog\u00eda del\u00a0Hospital Universitari Son Espases\u00a0y el\u00a0Institut de Investigaci\u00f3n Sanit\u00e0ria de les Illes Balears han participado en un estudio\u00a0de eficacia de monoterapia con odronextamab en pacientes con linfoma difuso de c\u00e9lulas B grandes reca\u00eddo\/refractario.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/\" \/>\n<meta property=\"og:site_name\" content=\"bip4ex\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-21T05:17:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.infosalut.com\/images\/noticies\/institucions\/ins-epr159.jpg\" \/>\n<meta name=\"author\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\\\/\"},\"author\":{\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\"},\"headline\":\"Odronextamab en pacientes con linfoma difuso de c\u00e9lulas B grandes reca\u00eddo\\\/refractario\",\"datePublished\":\"2025-10-21T05:17:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\\\/\"},\"wordCount\":60,\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.infosalut.com\\\/images\\\/noticies\\\/institucions\\\/ins-epr159.jpg\",\"articleSection\":[\"Noticias\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\\\/\",\"name\":\"Odronextamab en pacientes con linfoma difuso de c\u00e9lulas B grandes reca\u00eddo\\\/refractario - bip4ex\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.infosalut.com\\\/images\\\/noticies\\\/institucions\\\/ins-epr159.jpg\",\"datePublished\":\"2025-10-21T05:17:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.infosalut.com\\\/images\\\/noticies\\\/institucions\\\/ins-epr159.jpg\",\"contentUrl\":\"https:\\\/\\\/www.infosalut.com\\\/images\\\/noticies\\\/institucions\\\/ins-epr159.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Odronextamab en pacientes con linfoma difuso de c\u00e9lulas B grandes reca\u00eddo\\\/refractario\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"name\":\"bip4ex\",\"description\":\"Vigilancia Tecnol\u00f3gica\",\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\",\"name\":\"Helloproject.es\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"contentUrl\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"width\":322,\"height\":365,\"caption\":\"Helloproject.es\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\",\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/author\\\/luismi\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Odronextamab en pacientes con linfoma difuso de c\u00e9lulas B grandes reca\u00eddo\/refractario - bip4ex","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/","og_locale":"es_ES","og_type":"article","og_title":"Odronextamab en pacientes con linfoma difuso de c\u00e9lulas B grandes reca\u00eddo\/refractario","og_description":"El Departamento de Hematolog\u00eda del\u00a0Hospital Universitari Son Espases\u00a0y el\u00a0Institut de Investigaci\u00f3n Sanit\u00e0ria de les Illes Balears han participado en un estudio\u00a0de eficacia de monoterapia con odronextamab en pacientes con linfoma difuso de c\u00e9lulas B grandes reca\u00eddo\/refractario.","og_url":"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/","og_site_name":"bip4ex","article_published_time":"2025-10-21T05:17:22+00:00","og_image":[{"url":"https:\/\/www.infosalut.com\/images\/noticies\/institucions\/ins-epr159.jpg","type":"","width":"","height":""}],"author":"Luis Miguel Mej\u00edas Ramos","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Luis Miguel Mej\u00edas Ramos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/#article","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/"},"author":{"name":"Luis Miguel Mej\u00edas Ramos","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca"},"headline":"Odronextamab en pacientes con linfoma difuso de c\u00e9lulas B grandes reca\u00eddo\/refractario","datePublished":"2025-10-21T05:17:22+00:00","mainEntityOfPage":{"@id":"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/"},"wordCount":60,"publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/#primaryimage"},"thumbnailUrl":"https:\/\/www.infosalut.com\/images\/noticies\/institucions\/ins-epr159.jpg","articleSection":["Noticias"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/","url":"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/","name":"Odronextamab en pacientes con linfoma difuso de c\u00e9lulas B grandes reca\u00eddo\/refractario - bip4ex","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/#website"},"primaryImageOfPage":{"@id":"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/#primaryimage"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/#primaryimage"},"thumbnailUrl":"https:\/\/www.infosalut.com\/images\/noticies\/institucions\/ins-epr159.jpg","datePublished":"2025-10-21T05:17:22+00:00","breadcrumb":{"@id":"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/#primaryimage","url":"https:\/\/www.infosalut.com\/images\/noticies\/institucions\/ins-epr159.jpg","contentUrl":"https:\/\/www.infosalut.com\/images\/noticies\/institucions\/ins-epr159.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/helloproject.es\/vigilancia\/odronextamab-en-pacientes-con-linfoma-difuso-de-celulas-b-grandes-recaido-refractario\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/helloproject.es\/vigilancia\/"},{"@type":"ListItem","position":2,"name":"Odronextamab en pacientes con linfoma difuso de c\u00e9lulas B grandes reca\u00eddo\/refractario"}]},{"@type":"WebSite","@id":"https:\/\/helloproject.es\/vigilancia\/#website","url":"https:\/\/helloproject.es\/vigilancia\/","name":"bip4ex","description":"Vigilancia Tecnol\u00f3gica","publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/helloproject.es\/vigilancia\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/helloproject.es\/vigilancia\/#organization","name":"Helloproject.es","url":"https:\/\/helloproject.es\/vigilancia\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/","url":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","contentUrl":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","width":322,"height":365,"caption":"Helloproject.es"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca","name":"Luis Miguel Mej\u00edas Ramos","url":"https:\/\/helloproject.es\/vigilancia\/author\/luismi\/"}]}},"_links":{"self":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/185297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/comments?post=185297"}],"version-history":[{"count":0,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/185297\/revisions"}],"wp:attachment":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/media?parent=185297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/categories?post=185297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/tags?post=185297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}